CTSS inhibitors are in phase I and II clinical trials for treatment of autoimmune diseases such as rheumatoid arthritis and SS as well as other diseases associated with extracellular matrix degradation that may have autoimmune components such as abdominal aortic aneurysm. This evidence concerns the gene CTSS and autoimmune disease.